Oral Agent for Diabetic Macular Edema Misses Mark but Still Shows Promise
11/05/2026
Diabetes is a leading cause of vision loss, particularly due to conditions such as diabetic macular edema (DME). Recent research
Aprobación de un nuevo parche de terapia hormonal genérico Recentemente, la FDA aprobó el primer genérico del sistema transdérmico de…
Read more →
Diabetes is a leading cause of vision loss, particularly due to conditions such as diabetic macular edema (DME). Recent research
Introducción Heralding a “step forward on testosterone therapy for men,” the FDA announced an initiative to support a potential new
Treatment with oral semaglutide (Rybelsus) significantly improved motivation measures in patients with major depressive disorder (MDD), according to a secondary
Colorectal cancer prevention has been framed around a simple principle: find polyps early, remove them, and repeat colonoscopy to prevent
Introducción Cardiovascular protection with GLP-1 receptor agonists may benefit patients undergoing certain transcatheter procedures, according to two observational studies. When